Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1/2 4Phase 1 4Phase NA 3Phase 3 1Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 74Breast 62Genitourinary 38Thoracic 35Tumor-Agnostic 28CNS 24Dermatologic 20Sarcoma 15Head & Neck 7Gynecologic 5Other hematologic neoplasm 4Endocrine 2Classical hematology 2Plasma cell 1Other solid neoplasm 1NET 1

Conditions

Neuroendocrine Tumors 32Gastro-enteropancreatic neuroendocrine tumor 6Carcinoid Tumor 4Adenoma, Islet Cell 3Serotonin Syndrome 2Parkinson Disease 2Neuroblastoma 2Neoplasms 2Congenital Hyperinsulinism 2Advanced Gastroenteropancreatic Neuroendocrine Tumor 2Thymus Neoplasms 1Pancreatic Neuroendocrine Tumors in MEN1 1Pancreatic Neuroendocrine Tumors (pNET) 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors in Lung 1Neuroectodermal Tumors, Primitive 1Neoplasm Metastasis 1Melanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms Neoplasms 1Lymphoma, Follicular 1Liposarcoma 1Lewy Body Disease 1Insulinoma 1Hypoglycemia 1Hyperinsulinism 1Flushing 1Fibrosarcoma 1Disease 1Digestive Neuroendocrine Tumors 1Diarrhea 1Carcinoid Tumors, Intestinal 1

Interventions

3-Iodobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Neoplasm Metastasis × NET × Clear all
NCT00037869 2018-10-31

High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors

M.D. Anderson Cancer Center

Phase 3 Completed
15 enrolled
EndocrineNET

Neoplasm Metastasis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡